Table 7.
Characteristics and outcome of canine patients treated with chemotherapy alone for refractory cancers
| PATIENT | AGE | TUMOR |
PREV. TREATMENT |
THERAPY | OUTCOME (MONTHS) |
|---|---|---|---|---|---|
| MIXED | 11 | LSA | MADISON + MOPP |
MADISON | PD 1 |
| SETTER | 6 | ALL | MADISON + MOPP |
MADISON | PD 1 |
| BOXER | 9 | SKIN CARCINOMA |
DOXORUBICIN CARBOPLATIN |
CARBOPLATIN | PR 2 |
| WHWT | 8 | LSA | MADISON + MOPP |
MADISON | PR 1 |
| ROTTW | 7 | LSA | MADISON + MOPP |
MADISON | PR 3 |
| GERMAN | 9 | LSA | MADISON + MOPP |
MADISON | PD 1 |
| SHEPHERD | MOPP | ||||
| LABRADOR | 9 | LSA | MADISON + MOPP |
MOPP | PD 2 |
| MIXED | 10 | MAMMARY CARCINOMA |
DOXORUBICIN CARBOPLATIN |
DOXORUBICIN | PR 1 |
| DOGO | 10 | LIPOSARCOMA | DOXORUBICIN CARBOPLATIN |
CARBOPLATIN | PD 1 |
| MIXED | 10 | MAMMARY CARCINOMA |
DOXORUBICIN CARBOPLATIN |
CARBOPLATIN | PR 2 |
Abbreviations: ALL: acute lymphocytic leukemia; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; WHWT: west highland white terrier.
Drugs schedule: doxorubicin 30 mg/m2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m2 every 21 days, mitoxantrone 6 mg/m2 every 21 days. For Madison and MOPP protocols see table 4 and 5.